TITLE

Oral cladribine was more effective than placebo for relapsing-remitting multiple sclerosis

AUTHOR(S)
Hughes, James
PUB. DATE
May 2010
SOURCE
ACP Journal Club;5/18/2010, Vol. 152 Issue 5, p7
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a study that discusses the effective use of drugs such as oral cladribine and placebo in patients with relapsing-remitting multiple sclerosis (MS). As stated, doses of oral cladribine and placebo were given to thousands of patients during the clinical trail of MS. However, it concludes that doses of oral cladribine are more effective than placebo but its higher dose could release serious adverse events including lymphocytopenia, infections and infestations, and neoplasia.
ACCESSION #
51696575

 

Related Articles

  • Oral fingolimod was more effective than placebo for relapsing-remitting multiple sclerosis. Hughes, James // ACP Journal Club;5/18/2010, Vol. 152 Issue 5, p6 

    The article presents a study that discusses the effective use of drugs such as oral fingolimod and placebo in patients with relapsing-remitting multiple sclerosis (MS). As stated, doses of oral fingolimod and placebo were given to thousands of patients during the clinical trail of MS. However,...

  • Untitled.  // BioWorld Today;12/10/2009, Vol. 20 Issue 237, p3 

    The article reports on the Phase III STAR trial of Zenvia versus placebo in pseudobulbar affect (PBA) secondary to amyotrophic lateral sclerosis (ALS) or multiple sclerosis being conducted by Avanir Pharmaceuticals Inc. According to additional data from the subset of ALS patients, both doses of...

  • Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. Bar-Or, Amit; Gold, Ralf; Kappos, Ludwig; Arnold, Douglas; Giovannoni, Gavin; Selmaj, Krzysztof; O'Gorman, John; Stephan, Monica; Dawson, Katherine // Journal of Neurology;Sep2013, Vol. 260 Issue 9, p2297 

    In the double-blind, placebo-controlled, Phase 3 DEFINE study in patients with relapsing-remitting multiple sclerosis, oral BG-12 (dimethyl fumarate) significantly reduced the proportion of patients relapsed (primary endpoint), the annualized relapse rate (ARR), and confirmed disability...

  • Improving functional outcomes in patients with multiple sclerosis.  // British Journal of Hospital Medicine (17508460);Nov2008, Vol. 69 Issue 11, p613 

    The article reports on the study concerning the effect of the drug Tysabri (natalizumab) in patients with multiple sclerosis. A post-hoc analysis has shown that the drug increases the chance of achieving sustained improvement in physical disability over 2 years compared to placebo. More...

  • Use of immune globulin therapy for multiple sclerosis. Walling, Anne D. // American Family Physician;11/1/1997, Vol. 56 Issue 7, p1880 

    Presents a summary of the article `Randomised Placebo-Controlled Trial of Monthly Intravenous Immune Globulin Therapy in Relapsing-Remitting Multiple Sclerosis,' by F. Fazekas from the journal `Lancet' dated 1997. Management for multiple sclerosis; Result of the study on patients receiving...

  • Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Wade, Derick T.; Collin, Christine; Stott, Colin; Duncombe, Paul // Multiple Sclerosis (13524585);Jun2010, Vol. 16 Issue 6, p707 

    Objective: To determine the efficacy of Sativex (USAN: nabiximols) in the alleviation of spasticity in people with multiple sclerosis. Methods: The results from three randomized, placebo-controlled, double-blind parallel group studies were combined for analysis. Patients: 666 patients with...

  • Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study. Morrow, Sarah; Smerbeck, Audrey; Patrick, Kara; Cookfair, Diane; Weinstock-Guttman, Bianca; Benedict, Ralph // Journal of Neurology;Feb2013, Vol. 260 Issue 2, p489 

    Multiple sclerosis (MS) causes cognitive impairment including slowed processing speed and problems with learning and memory. Stimulants are attractive candidates for improving mental speed but carry risk of addiction and other adverse behavioral effects. Lisdexamfetamine dimesylate (LDX) is a...

  • Novartis reports encouraging data from Phase III multiple sclerosis study.  // PharmaWatch: CNS;Jun2012, Vol. 11 Issue 6, p14 

    The article reports on the results of the Phase III FREEDOMS extension study conducted by Novartis AG which examines the improvements in patients with multiple sclerosis (MS) who switched from placebo to Gilenya. It notes that 1033 patients have participated in the study wherein 90 percent of...

  • Multiple sclerosis: transformation, freedom and clarity for our patients? Strupp, Michael // Journal of Neurology;Mar2010, Vol. 257 Issue 3, p494 

    The article examines three studies that deal with oral therapeutics for relapsing-remitting multiple sclerosis published in an issue of the "New England Journal of Medicine." The CLARITY study focused on a placebo-controlled trial of oral cladribine and the adverse events associated with its...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics